The objectives of this study were to characterize AR expression in advanced PC, to determine its association with BCL2, to elucidate their clinical significance, and to uncover mechanisms of regulation, with the aim of exploring whether BCL2 could represent a valid therapeutic target and/or biomarker (prognostic and/or predictive). The gene discussed is AR; the disease is pachyonychia congenita.